Transcript Document

New clinical trial for adolescents and adults
with Fragile X Syndrome 14-50 years of age
PURPOSE: to study the effectiveness and safety of a new
drug that is being developed to improve the symptoms of
Fragile X Syndrome
Sponsored by
Pharmaceuticals
Taking place at The Kennedy Krieger Institute, Baltimore, Maryland
PI: Michael V. Johnston, MD
Kennedy Krieger Institute
Co-I: Dejan Budimirovic, MD
Director, Fragile X Clinic
Kennedy Krieger Institute
Approved May 8, 2013
Co-I: Tanjala Gipson, MD
Kennedy Krieger Institute
This research study is free. You will be given $50 for
reimbursement for travel and related expenses for each
completed visit. Call 443-923-7619 for more information.
Protocol Number: NA_00049393